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Abstract 
Background: The objective of this randomized trial was to compare 
the effects of mesalazine and nortriptyline on relief of abdominal pain, 
discomfort, abnormal bowel habits and quality of life in patients with 
diarrhea-predominant irritable bowel syndrome (IBS-D). 
Methods: In this triple blinded, randomized clinical trial, 44 patients 
with irritable bowel syndrome with diarrhea were randomly assigned 
to receive mesalazine (500 mg tablet orally, twice a day) or 
nortriptyline (10 mg tablet orally, once daily). IBS-D was diagnosed 
according to the Rome Ⅲ criteria. Before allocation, all patients 
completed the Beck questionnaire for screening for depression, and the 
informed consent form. 
Results: Change score for abdominal pain severity was significantly 
higher for mesalazine than for nortriptyline (208.5±80.9 V.s 
146.8±105.6) and change score for days with pain was not significantly 
different between two arms (3.9±2.8 V.s 2.8±3.0). The results show that 
the change score of satisfaction with bowel habits (56.2±20.2 V.s 
37.5±24.9) and quality of life (42.0±26.7 V.s 26.3±18.6) in the 
mesalazine-treated group is greater than in the nortriptyline group. 
Conclusions: This study showed that mesalazine, as an anti-
inflammatory agent for treatment of IBS-D in patients without 
psychological disorders, is more effective than nortriptyline. 
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Introduction 
Irritable bowel syndrome (IBS) is the most common 
disorder among functional gastrointestinal disorders, affecting 
10–20% of adults and adolescents in USA, 8.6% in Singapore, 
and 14% in Pakistan.1,2 IBS is a functional bowel complaint in 
which abdominal pain is associated with defecation or change 
in bowel habit.2 Approximately 20% of persons in the 
developed world have IBS symptoms at some time in their 
lives.3 IBS is common in western Europe and North America, 
and many aspects of its epidemiology, risk factors, and natural 
history have been described in these regions.4 Women are at 
slightly higher risk for IBS than men.5 IBS decreases the 
patient’s quality of life through repeated waxing and waning of 
symptoms over a long period.6 Despite intensive research over 
the past two decades, the etiology of IBS remains poorly 
understood, thus leading to limited effective treatments for 
patients with these disorders.1 At present, no effective and 
optimal treatment has been determined.7 
IBS with diarrhea (IBS-D) as a subtype accounts for 23.4% 
of patients with IBS.8 The mechanism and pathogenesis of IBS-
D are not completely understood and different drug categories 
(antispasmodic, Dopamine antagonist, 5-HT3 antagonist, 
sedatives and probiotics), diet and life style modification have 
been used as symptomatic therapies.9 Although psychological 
factors such as depression, stress and anxiety have not been 
shown to cause or influence the onset of IBS, psychological 
factors play a role in the persistence and perceived severity of 
abdominal symptoms.2 Evidence suggests there is a relation 
between IBS and stress that can motivate the mast cells, and in 
IBS-D patients mast cell numbers have been shown to 
increase.10 We hypothesize that treatment with mesalazine, 
through its anti-inflammatory effects, will reduce the number 
of mast cells and consequently reduce abdominal pain and 
diarrhea.11 The Corinaldesi trial that had the goal of assessing 
the effect of mesalazine on mucosal immune cells in 20 
patients with IBS indicated a decrease in mast cell numbers, a 
reduction in inflammatory cells and an improvement in general 
well-being.12 In a review of the study protocol trial shown in a 
multicenter trial, 108 participants with diarrhea-predominant 
IBS randomized for intervention group with 12-week course of 
2 g mesalazine granules twice a day; the control group was a 
blinded placebo granule formulation.11 In another recent study, 
the effects of mesalazine alone, a combined therapy of 
mesalazine with lyophilised Saccharomyces boulardii (Sb) or 
alone on symptoms of IBS-D patients were assessed. In this 
study, improvement in the symptom score was greater with 
mesalazine alone or combined with Sb compared with Sb 
treatment alone.13 
The objective of this randomized trial was to compare the 
effects of mesalazine and nortriptyline on patients with 
diarrhea-predominant irritable bowel syndrome (IBS-D) in 
relieving abdominal pain, discomfort and abnormal bowel 
habits and stool frequency recorded daily. 
Materials and Methods  
A triple blind, randomized clinical trial was conducted in 
the gastrointestinal clinic of Imam Hossein Hospital in 
Shahroud, northeast of Iran. This study was conducted from 
January 2013 to March 2014. In this study, 44 patients with 
IBS with diarrhea were randomly assigned to receive 
mesalazine or nortriptyline (Figure 1). IBS-D was diagnosed 
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according to the Rome Ⅲ criteria (mainly including abdominal 
pain, diarrhea and without any organic alteration).14 Random 
allocation was based on the order of entry; eligible patients 
received envelopes that included codes and based on these 
codes they were randomly assigned into mesalazine or 
nortriptyline groups based on a four block design. 
Patients were eligible for enrollment if they were aged 
between 18 and 65 years. Before allocation, all patients 
completed the Beck questionnaire for screening for depression. 
The main exclusion criteria were the use of analgesic drugs, 
pregnant or breastfeeding women, patients with major 
depressive disorder according to DSM-IV-TR and Beck 
Depression Inventory, gastrointestinal bleeding, presence of 
any finding of organic disorders in the lab tests, or organic 
disorders in the colonoscopies of high-risk patients, use of 
illicit drugs, and presence of mixed and constipation-
predominant IBS. All patients provided informed consent. This 
study was approved by the institutional review board of 
Shahroud University of Medical Sciences (code: 9104) and was 
registered with the Iranian Registry of Clinical Trial (IRCT ID: 
IRCT201506171647N4). 
Patients who met the inclusion criteria were recruited and 
randomized in two groups to receive mesalazine (500 mg tablet 
orally, twice a day) as intervention, and nortriptyline (10 mg 
tablet orally, once daily) for the control group for 8 weeks. 
Randomization was performed by a computer-generated table 
in blocks of 4. All patients and investigators and data analyzers, 
except for the study coordinator, remained blinded to the 
randomization process until study completion. 
After filling in the informed consent forms, patients were 
referred to a particular pharmacy where a pharmacy technical 
assistant delivered drugs to them free of charge, in similar but 
sealed boxes with specific codes and with no labels. 
The baseline (week 0) stool form, stool frequency, and 
visual analog scale score (from 0 to 100) for symptoms 
associated with IBS were recorded using IBS Severity Scoring 
system (IBS, SSS). 
The IBS, SSS (15) had two parts: i) IBS severity score, and 
ii) other therapeutic features. Main outcome measure variables 
were measured with the (IBS,SSS) (15), which contains five 
100 point scales (range: not pain (0), not very severe (25), quite 
severe (50), severe (75) and very severe (100)), that assess the 
severity of abdominal pain, frequency of abdominal pain 
expressed as the number of days that you get the pain over the 
preceding 10 days, dissatisfaction with bowel habits, 
interference with quality of life, and abdominal distension 
(bloating, swollen, or thigh tummy). The combination of these 
5 scales led to a total possible score of 500 as overall IBS 
severity score. In part 2, for all patients other clinical signs 
consisting of incomplete evacuation, mucus in stools, site of 
pain, and stool frequency recorded daily were measured and 
compared between groups at the baseline and 8 weeks after the 
intervention. How IBS affected and interfered with quality of 
life in general was assessed with a line scale range from 0 to 
100 (‘Not at all’ till ‘completely’). 
Data were analyzed using SPSS software. Continuous 
variables were analyzed using Student’s t tests and categorical 
variables were analyzed using Chi-square tests or Fisher’s 
exact tests when 20% of expected frequencies were less than or 
equal to 5. To evaluate the change in symptom scores over time 
and to compare scores between the groups, we used change 
scores between before and after the investigation with t test. 
Results were considered statistically significant when p values 
were <0.05. 
Results 
Figure 1 shows the study flow chart. Among subjects 
screened for diarrhea-predominant IBS, 44 were eligible for the 
study. Of these, 22 were assigned to receive mesalazine and the 
other 22 to receive nortriptyline. Four patients dropped out and 
40 patients with IBS-D in arm A and B completed the study. 
These patients were included in the intention-to-treat analysis. 
Demographic and baseline characteristics of the 40 participants 
are shown in Table 1. Patients in the two groups were balanced 
in demographic characteristics. No statistical difference was 
observed between the mean abdominal pain scores for the two 
groups. The mean baseline involving days with pain was 
comparable between the two groups. 
Figure 1. Chart of trial 
Analysis  Analysi
s  
Completing trial 
at 8 weeks  
Completing trial 
at 8weeks  
Excluded: Did not 
meet or call, N=2 
Excluded: Did not 
meet or call, N=2 
Patients screened with IBS (N=85) 
Random allocation 
Detect IBS with Diarrhea (N=44)  
Nortriptyline: N=22 Mesalazine: N=22 
41 Patients 
excluded (according 
to exclusion criteria) 
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According to the results in Table 2, a higher change score 
in abdominal pain of mesalazine-treated patients than in 
nortriptyline-treated patients indicated a significant relief in 
pain for mesalazine rather than for nortriptyline. The frequency 
of patients with an abdominal pain severity score of <25 (not 
very severe) for mesalazine and nortriptyline groups was 20 
(100%) and 19 (95%), respectively. The pain component of the 
questionnaire incorporated both severity and duration. The 
latter was assessed by asking the patient to recall the 
occurrence of pain over the preceding 10 days. The change 
score for days involved with pain was not significantly 
different between the two groups. There was no significant 
change score in abdominal distension scores between the two 
groups. The frequency of patients with abdominal distension 
score of <25 (not very severe) after the treatment was for 19 
(95%) for the mesalazine group and 17 (80%) for the 
nortriptyline group. The results of Table 2 show that the change 
score for satisfaction with a visit to toilet and quality of life in 
mesalazine-treated group is greater than in nortriptyline group. 
Summation of five 100 point scores, described as IBS severity 
score, resulted in a significant change in the overall IBS 
severity score in both groups with predominance of mesalazine 
group.  
Comparison between number of visits to toilet per day 
(opening of bowels) in the two groups before and after the 
intervention showed a significant reduction (4.7±1.5 vs. 
2.7±1.3 for the nortriptyline group, and 5.9±3.3 vs. 2.0±1.3 for 
mesalazine group). In contrast, mesalazine had a significantly 
better effect on number of opening of bowel/day between the 
two groups (P=0.019). 
The results of this study show that use of mesalazine in 
contrast to nortriptyline did not have a better effect on mucus 
passage, straining on defecation and incomplete evacuation 
feeling after defecation (Table 3); however, the intervention in 
the two groups reduced the symptoms of IBS-D. No serious 
drug-related adverse events were reported during the study. 
Table 3. Comparison of the other IBS symptoms after intervention 
 Mesalazine 
(N=20) 
Nortriptyline 
(N=20) 
P.V* 
Mucus passage (%)  1(5) 3(15) 0.72 
Stool urgency (%) 1(5) 7(35) 0.018 
Straining on defecation (%) 2(10) 7(35) 0.058 
Feeling of incomplete evacuation 
after defecation (%) 
1(5) 2(20) 0.151 
*Fisher exact test 
Discussion 
The etiology of IBS is unknown. However, it has been 
demonstrated that mental stress and psychological distress are 
correlated with development of IBS.16 Due to the varied range 
of symptoms in patients with IBS, existing pharmacological 
treatments are largely targeted at symptom relief. Available 
therapies remain unsatisfactory and provide only symptomatic 
relief at best for many patients with IBS. Clinical trials have 
shown that IBS patients without a depressive disorder can 
benefit from low-dose tricyclic antidepressants (TCA) 
therapy.17 TCA agents appear to normalize gastrointestinal (GI) 
motility and reduce visceral pain.18,19 In this study, we 
hypothesized that mesalazine treatment, through its anti-
inflammatory effects, will reduce the number of mast cells and 
thereby reduce abdominal pain and diarrhea.  
The results of this study indicate that the use of mesalazine 
and nortriptyline has a positive effect on reducing IBS-D 
severity score over an 8- week interval. In contract, the 
improvement of the symptom score was greater with 
mesalazine compared with nortriptyline-treated patients. In a 
randomized trial on 360 patients with varying subtypes of IBS, 
treatment of IBS patients with mesalazine significantly reduced 
intensity and duration of pain in all subtypes of IBS.20 Andrews 
et al. showed that mesalazine treatment is associated with a 
decrease in fecal bacteria abundance. In this study the patients 
responded favorably to mesalazine, with significant decrease in 
days with discomfort and increases in bowel movement 
Table 1. Demographic and baseline characteristics of the study participants with irritable bowel syndrome 
 Mesalazine (N=20) Nortriptyline (N=20) P V 
Sex    
- Male 14(70.0) 12(60.0) 
0.507 
- female 6(30.0) 8(40.0) 
Age (mean±sd) 36.9±7.2 37.2±12.3 0.9 
BMI(mean±sd) 24.9±3.8 24.0±3.3 0.44 
Abdominal pain score (mean±sd) 48.8±19.0 46.8±22.1 0.76 
Mean involved days with pain (mean±sd) 5.4±3.0 4.8±2.9 0.69 
Table 2. Comparison of mean differences of IBS- Severity Scoring system before and after intervention in the study participants with irritable bowel syndrome 
 Mean difference (before and after change score)  
 
Mesalazine 
(N=20) 
Nortriptyline 
(N=20) 
P.V 
Abdominal pain score 37.5±18.7 27.2±21.6 0.047 
Involved days with pain over the preceding 10 days 3.9±2.8 2.8±3.0 0.20 
Abdominal distension score 33.2±27.7 28.2±28.2 0.57 
Satisfaction with bowel habits 56.2±20.2 37.5±24.9 0.007 
Interference with quality of life 42.0±26.7 26.3±18.6 0.047 
Overall IBS severity score 208.5±80.9 146.8±105.6 0.045 
Opening of bowels per day 3.9±3.2 2.0±1.5 0.019 
Vahedi et al 
International Journal of Health Studies 2017;3(1)       |        29 
satisfaction.21 Corinaldesi and et al. assessed the effect of 
mesalazine compared with placebo on mucosal immune cells in 
20 patients with IBS. They showed that mesalazine 
considerably reduced immune cells compared with placebo, 
and mesalazine significantly increased general well-being 
(P=0.038), but had no significant effects on abdominal pain, 
bloating or bowel habits12 unlike in our study. In a study in 
Iran, the researchers assessed the effect of amitriptyline (10 mg 
for 2 months) compared with placebo in treating of IBS-D. 
They showed that the amitriptyline group had greater reduction 
in the incidence of loose stool and feeling of incomplete 
defecation.22 
Our results showed that other symptoms of IBS-D such as 
mucus passage, straining on defecation and feeling of 
incomplete evacuation in both treatment groups improved after 
8 weeks of treatment period. However, there were no 
advantages for mesalazine compared with nortriptyline.  
In this triple blinded, randomized clinical trial, treatment 
with mesalazine and nortriptyline significantly relieved 
abdominal pain and discomfort, decreased stool frequency and 
increased quality of life in patients with diarrhea-predominant 
IBS (IBS-D). Mesalazine in contrast to nortriptyline had a 
better effect on abdominal pain severity, quality of life and 
satisfaction with bowel habit. Therefore we recommend 
mesalazine as an anti-inflammatory agent for treatment of IBS-
D in patients without psychological disorders. 
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